Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
1.130
0.00 (0.00%)
At close: Apr 6, 2026, 4:00 PM EDT
1.140
+0.010 (0.88%)
Pre-market: Apr 7, 2026, 6:42 AM EDT
Inovio Pharmaceuticals Employees
Inovio Pharmaceuticals had 112 employees as of December 31, 2025. The number of employees decreased by 22 or -16.42% compared to the previous year.
Employees
112
Change (1Y)
-22
Growth (1Y)
-16.42%
Revenue / Employee
$583
Profits / Employee
-$758,446
Market Cap
92.20M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 112 | -22 | -16.42% |
| Dec 31, 2024 | 134 | 12 | 9.84% |
| Dec 31, 2023 | 122 | -62 | -33.70% |
| Dec 31, 2022 | 184 | -133 | -41.96% |
| Dec 31, 2021 | 317 | 55 | 20.99% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Pyxis Oncology | 56 |
| Vivani Medical | 42 |
| Aardvark Therapeutics | 40 |
| TuHURA Biosciences | 22 |
| ProMIS Neurosciences | 11 |
| Aldeyra Therapeutics | 8 |
| Coya Therapeutics | 8 |
INO News
- 4 days ago - INOVIO Announces Pricing of $17.5 Million Public Offering - PRNewsWire
- 5 days ago - INOVIO Announces Proposed Public Offering - PRNewsWire
- 5 days ago - INOVIO to Participate in Upcoming Scientific Conference - PRNewsWire
- 24 days ago - Inovio Stock Up On Earnings, Pipeline Progress - Benzinga
- 25 days ago - INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - PRNewsWire
- 4 weeks ago - INOVIO to Participate in Upcoming Scientific Conferences - PRNewsWire
- 4 weeks ago - INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 - PRNewsWire
- 4 weeks ago - Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) - PRNewsWire